

Frequency of variants of hereditary cancer risk syndrome in 1682 Brazilian patients genotyped by next-generation sequencing

Short Title: Variants of hereditary cancer risk in 1682 Brazilian patients

Jarbas Maciel de Oliveira^{1,2*}, Nuria Bengala Zurro³, Antonio Victor Campos Coelho³, Marcel Pinheiro Caraciolo³, Rodrigo Bertollo de Alexandre³, George de Vasconcelos Carvalho Neto³, Ivana Grivicich² and João Bosco de Oliveira Filho^{3*}

¹ Hospital Memorial Arcoverde, Avenida José Bonifácio 1121, Arcoverde, Pernambuco 56503-740, Brazil

² Programa de Pós Graduação em Biologia Celular e Molecular Aplicada à Saúde, Universidade Luterana do Brasil, Av. Farroupilha 8001, Canoas - Rio Grande do Sul 92425-020, Brazil

³ Hospital Israelita Albert Einstein, Avenida Albert Einstein 627, São Paulo 05652-900, Brazil

* Corresponding author

jarbasmaciel@yahoo.com.br (JMO) or joao.bosco@einstein.br (JBOF)

Funding: This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

1 Abstract

2 Hereditary cancer risk syndromes are a group of disorders caused by germline
3 variants in a growing number of genes. Most studies on hereditary cancer have
4 been conducted in white populations. Here we report the largest study in
5 Brazilian individuals with multiple, self-reported, ethnicities. We genotyped 1682
6 individuals from all regions of the country who were referred to genetic testing
7 for hereditary cancer risk with multigene Next-generation sequencing (NGS)
8 panels. Most were women, and had a personal and/or family history of cancer.
9 The majority of cancer cases were breast and ovarian. We identified a total of
10 321 pathogenic/likely pathogenic (P/LP) variants in 305 people (18.1%),
11 corresponding to 166 unique variants. These variants were distributed among
12 32 genes, and most were detected on *BRCA1* and *BRCA2* (129 patients, 26.2%
13 and 14.3% of all P/LP hits, respectively). The prevalence of any genes
14 transheterozygosity in our sample was 0.89% (15/1682). The *BRCA1/BRCA2*
15 double heterozygosity rate was 0.78% (1/129) for *BRCA* variants carriers and
16 0.06% (1/1682) overall. We classified patients according to the NCCN and
17 Brazilian National Health Agency (ANS) genetic testing recommendation
18 criteria. We found that the criteria had false negative rates of 17.3% and 44.2%,
19 meaning that both failed to detect a substantial part of P/LP positive patients.
20 Therefore, our results show that NGS adds to knowledge on the Brazilian
21 spectrum of germline variants associated with cancer risk and indicate that
22 Brazilian testing guidelines should be improved.

23

24 **Keywords:** breast cancer, cancer genomics, familial cancer history, population
25 genetics, colorectal cancer.

26 **Introduction**

27 Hereditary cancer risk syndromes are a group of disorders caused by
28 germline pathogenic variants in a growing number of genes. They are the main
29 predisposing factor in about 5-10% of all diagnosed cancers. Accurate genetic
30 diagnosis in patients with hereditary cancer risk syndromes may reduce
31 morbidity and mortality by allowing the adoption of specific preventative and
32 therapeutic measures. Additionally, family members at risk can be tested and
33 counseled, extending the clinical benefits to many individuals ¹.

34 Currently, there are over 30 hereditary cancer syndromes already
35 described, the most prevalent being hereditary breast and ovarian cancer
36 syndrome (HBOC). Other syndromes include Li-Fraumeni, Cowden, Lynch,
37 Familial Adenomatous Polyposis (APC), multiple Endocrine Neoplasia Type 1
38 or Wermer's Syndrome (MEN1), multiple Endocrine Neoplasia Syndrome - Type
39 2 (RET), and Von Hippel-Lindau Syndrome (VHL), to cite the most common.
40 Most syndromes are inherited in an autosomal-dominant manner, with variable
41 penetrance, and are caused by mutations in oncogenes or tumor suppressor
42 genes ². Although initially hard to diagnose genetically, the advent of next-
43 generation sequencing (NGS) has allowed for testing using panels with dozens
44 to hundreds of genes simultaneously and inexpensively ³. This has caused a
45 great increase in the clinical use of these NGS panels, while a growing body of
46 evidence show their clinical utility as compared to single-gene testing ^{4,5}.

47 Although large studies have been published on the diagnostic utility of
48 such panels, these are mostly restricted to white populations. The aim of this
49 study was to describe the frequency and type of germline pathogenic variants in
50 cancer susceptibility genes in patients with clinical criteria of hereditary cancer
51 syndrome by NGS in the genetically admixed Brazilian population.

52 **Materials and methods**

53 **Inclusion and exclusion criteria**

54 The cohort to the retrospective study included 1682 Brazilian patients
55 who received a multi-gene NGS panel for risk of hereditary cancer in the
56 Genomika diagnostics unit, a genetics laboratory of the Albert Einstein Israeli
57 Hospital (Genomika-Einstein hereafter). As this study took place in a private
58 diagnostic laboratory this cohort was not specifically selected for any sex, age,
59 ethnicity, or history of cancer. Both patients with or without criteria for hereditary
60 risk cancer syndrome were considered. After genetic assessment we classified
61 patients according to the USA National Comprehensive Cancer Network
62 (NCCN, www.nccn.org) guidelines: genetic/familial high-risk assessment
63 versions 3.2019 and 1.2020. Non-Brazilian patients were excluded.

64

65 **Research ethics statement**

66 This project was approved by the Institutional review board from the
67 Research Ethics Committee of the Institute of Integral Medicine Professor
68 Fernando Figueira (CEP-IMIP) in Recife, Pernambuco and all individuals

69 provided written consent for multi-gene testing (protocol number CAAE
70 29567220.4.1001.0071).

71

72 **Multigene genotyping panel**

73 Genotyping was performed through panels that covered the entire coding
74 region including 20 bp flanking each exon and noncanonical splice region.

75 Patients were sequenced with panels that ranged from 27 to 78 genes,
76 including genes mostly associated with hereditary cancer risk, such as *APC*,
77 *ATM*, *BARD1*, *BMP1A*, *BRCA1*, *BRCA2*, *CDH1*, *CDK4*, *CHEK2*, *EGFR*,
78 *EPCAM*, *GREM1* *HOXB13*, *MEN1*, *MITF*, *MLH1*, *MRE11A*, *MSH2*, *MSH6*,
79 *MUTYH*, *NBN*, *PALB2*, *PMS2*, *POLD1*, *POLE*, *PTEN*, *RAD50*, *RAD51C*,
80 *RAD51D*, *RB1*, *RET*, *SMAD4*, *STK11*, *TP53*, *VHL*. The complete list of genes is
81 available in the Table A.1).

82

83 **Library preparation for NGS**

84 Laboratory procedures were performed at Genomika-Einstein units
85 (Recife - PE and São Paulo - SP). Genomic DNA was extracted from peripheral
86 blood or saliva by automation (QIASymphony platform, QIAGEN, Hilden,
87 Germany) using the DNA Mini Kit extraction kit (QIAGEN). The quality and
88 quantity of the extracted DNA were assessed by fluorometry (Qubit, Thermo
89 Fisher, Waltham, Massachusetts). The genomic DNA was enzymatically
90 fragmented and enriched. The fragments were barcoded via multiplexed PCR
91 technology by QIAseq Targeted DNA Panels (CDHS 174272-2274 QIAGEN).
92 The genes were sequenced on MiSeq or Next-Seq 550 instruments (Illumina,

93 San Diego, CA) using MiSeq Reagent Kit v2 (300-cycles) or Next-Seq 550
94 High-throughput kit (300 cycles) with 100% coverage and 50X minimum depth.
95

96 **Sanger sequencing**

97 In cases where variant confirmation was deemed necessary (low read
98 depth, complex indels), the genotype was determined by conventional PCR
99 followed by Sanger sequencing on an ABI 3500 (Thermo Fisher, Waltham,
100 Massachusetts) automatic sequencer. The variant call was made via the
101 reference transcript from the ATG initiation codon aligned against the GRCh37 /
102 hg19 reference genome.

103

104 ***Alu* insertion identification**

105 Relevant genetic screenings of breast/ovarian cancer families of
106 Portuguese ancestry demonstrate that the c.156_157ins*Alu* variant is the most
107 frequent *BRCA2* rearrangement. Detection of this variant was performed as
108 published elsewhere ⁶ . Briefly, PCR of *BRCA2* exon 3 was performed and the
109 *Alu* insertion is detected by differential agarose gel electrophoresis.

110

111 **Variant classification and bioinformatic analysis**

112 Bioinformatic analysis was performed using GATK 3.0 best practices.
113 VCFs were annotated using Annovar and in-house databases. The clinical
114 significance of the variants was determined according to the criteria of the
115 American College of Genomics and Genetics (ACMG) 2015 guidelines for
116 sequence variant interpretation and 2018 guideline update ^{7, 8} . Each variant

117 classification were performed independently by two specialists. Allelic frequency
118 was examined through access to population databases as Genome
119 Aggregation Database (gnomAD) ⁹, Exome Aggregation Consortium (ExAC) ¹⁰,
120 and The 1000 Genomes Project ¹¹. Disease information were upload form
121 ClinVar ¹² and the Leiden Open Variation Database (LOVD) ¹³. All variant
122 information used for classification were updated and upgraded in an in-house
123 local knowledgebase.

124 **Results**

125 **Study sample characteristics and cancer histories**

126 Between July 2016 and July 2019, we collected samples and
127 clinical/demographic characteristics from 1682 Brazilian individuals referred to a
128 private laboratory to undergo genotyping with a cancer hereditary risk
129 multigenic panel (Table 1).

130 Among the individuals, 1557 (92.6%) were women with mean age of 47.4
131 \pm 12.3 (range 11-88) years and 125 (7.4%) were men with mean age of 51.4 \pm
132 15.2 (range 14-91) years. Regarding ethnic ancestry, 1007 (59.9%) individuals
133 reported unknown background, 330 (19.6%) reported having multiple ethnicities
134 (admixed), 259 (15.4%) white, 26 (1.5%) black, 22 (1.3%) Ashkenazi Jewish, 21
135 (1.2%) native indigenous and 17 Asian (1.0%) (Table 1).

136 Personal cancer history was reported by 1126 (66.9%) individuals, with
137 breast or ovary cancers identified in 971 individuals (57.7%); colorectal cancer
138 in 71 (4.2%); thyroid/parathyroid in 36 (2.1%); prostate cancer in 15 (0.9%);
139 stomach cancer in 14 (0.8%); uterus, kidney, and sarcomas in 13 each (0.8%);
140 leukemia in 11 (0.6%); non-melanoma skin and pancreas cancers in 9 each

141 (0.5%); and melanoma in 6 (0.4%). Other types of cancer (lung, liver, bladder,
142 larynx etc.) were identified in 17 individuals (1.0%). Overall, 268 individuals
143 (15.9%) did not present malignant neoplasms and for 293 individuals (17.4%)
144 the history information was not available.

145 Family cancer history (considering first-, second- or third-degree
146 relatives) was reported by 1182 (70.3%) individuals: 806 (47.9%) reported
147 breast cancer family history; 310 (23.0%) colorectal cancers; 339 (20.2%)
148 prostate cancer; 219 (13.0%) head and neck tumors; 172 (10.2%) lung cancer;
149 155 (9.2%) stomach cancer; 119 (7.1%) breast and ovarian and 48 (2.9%)
150 ovarian cancer exclusively. No family history was reported by 163 (9.7%)
151 individuals and 337 (20.0%) did not provide information regarding family history
152 (Table 1, Table A.2).

153

154 **Genetic findings**

155 Pathogenic or likely pathogenic variants were found in 305 (18.1%) of the
156 1682 individuals. Additionally, 1252 variants of uncertain significance (VUS)
157 were found in 753 (44.8%) individuals (Fig. 1A, Table A.3). The remaining 624
158 (37.1%) patients did not present any variants of clinical interest whatsoever
159 (negatives).

160 The 305 individuals collectively had 321 pathogenic/likely pathogenic
161 variant hits (corresponding to 166 unique variants) in 32 genes: *APC*, *ATM*,
162 *BARD1*, *BRCA1*, *BRCA2*, *BRIP1*, *CDH1*, *CDK4*, *CHEK2*, *EPCAM*, *FANCC*,
163 *MEN1*, *MITF*, *MLH1*, *MRE11A*, *MSH2*, *MSH6*, *MUTYH*, *NBN*, *PALB2*, *PMS2*,
164 *POLD1*, *PTCH2*, *PTEN*, *RAD50*, *RAD51*, *RAD51C*, *RAD51D*, *RB1*, *RECQL*,
165 *RET* and *TP53*.

166 The genes that most commonly presented pathogenic or likely
167 pathogenic variants were *BRCA1* (84/321 = 26.2%), *BRCA2* (46, 14.3%) and
168 *PALB2* (25, 7.8%). Lynch syndrome genes (*MLH1*, *MSH2*, *MSH6* and *PMS2*)
169 came next with 17 (5.3%) and were tied with *TP53*, also with 17 (5.3%) hits.
170 Next came *ATM* (15, 4.7%), *CHEK2* (14, 4.4%), *RAD51C* (9, 2.8%), *RAD51* (8,
171 2.5%), *RAD50* (7, 2.2%), *BRIP1* (6, 1.9%), *BARD1* (4, 1.2%), *PTEN* (4, 1.2%),
172 *RAD51D* (4, 1.2%) and *APC* (3, 0.9%). Other genes amounted 17 (3.0%)
173 variants (*NBN*, *RET*, biallelic *MUTYH*, *MITF*, *CDH1*, *EPCAM*, *FANCC*, *MRE11*,
174 *POLD1*, *RB1*, *RECQL*, *MEN1*, *CDK4* and *PTCH2*). Moreover, monoallelic
175 *MUTYH* variants, considered to have low penetrance, were detected in 42
176 (13.1%) cases (Fig. 1B).

177 In terms of unique variants, we detected 24 in *BRCA1*, 32 in *BRCA2*, 16
178 in *PALB2*, 16 in the Lynch syndrome genes, eight in *TP53*, 14 in *ATM*, eight in
179 *CHEK2*, six in *RAD51C*, nine in *RAD51*, two in *RAD50*, six in *BRIP1*, four in
180 *PTEN*, two in *RAD51*, three in *APC*, two in *NBN*, eight in *MUTYH*, two in *CDH1*
181 and one each in *BARD1*, *RET*, *MITF*, *EPCAM*, *FANCC*, *MRE11*, *POLD1*, *RB1*,
182 *RECQL*, *MEN1*, *CDK4* and *PTCH2*.

183 Among the 321 pathogenic/likely pathogenic variant hits, 84 (26.2%)
184 were point mutations in conserved splice sites, 73 (22.7%) were frameshift
185 deletions, 65 (20.2%) were missense point mutations, 58 (18.1%) were
186 nonsense point mutations, 22 (6.9%) were frameshift duplications, 10 (3.1%)
187 were frameshift insertions, four (1.3%) were frameshift indels, four inframe
188 deletions (1.3%), and a single inframe insertion (0.3%) (Fig. 1C).

189 Most of the 1252 VUS hits (corresponding to 886 unique variants) were
190 identified in *ATM* (198 hits, 15.8%), followed by *BRCA2* (86, 6.9%), *MHS6* (63,

191 5.0%), *BRIP1* (55, 4.4%), *RAD50* (52, 4.2%), *CHEK2* (38, 3.0%), *PALB2* (34,
192 2.7%), *MHS2* (31, 2.5%), *MLH1* (17, 1.4%), *TP53* (17, 1.4%), *BRCA1* (17,
193 1.4%). Other genes amounted to 644 (51.4%) VUS (Fig. 1D).

194 **Individuals with multiple variants (transheterozygotes)**

195 Among the 305 individuals with pathogenic/likely pathogenic variants,
196 290 (95.1%) were single heterozygotes, 14 (4.6%) presented two variants in
197 different genes (any two of these: *APC*, *ATM*, *BRCA1*, *BRCA2*, *CDK4*, *CHEK2*,
198 *MEN1*, *MUTYH*, *PALB2*, *PMS2*, *RAD51*, *RAD51C* or *TP53*) and a single patient
199 (0.3%) presented three pathogenic variants in different genes (*BRCA1*, *MSH6*
200 and *MUTYH*). The most common combination in the patients with two variants
201 was a variant in a high-penetrance gene, such as *BRCA1* and *BRCA2*,
202 alongside a variant with lower penetrance, such as monoallelic *MUTYH* or in
203 *CHEK2*. No patients presented more than one pathogenic/likely pathogenic
204 variants in the same gene (Fig. 2, Table A.4). We observed a single individual
205 *BRCA1/BRCA2* double heterozygote, making the double heterozygotes
206 prevalence among *BRCA* variants carriers about 0.78% (1/129) and 0.06%
207 (1/1682) overall. Thus, the overall transheterozygosity prevalence was about
208 0.89% (15/1682) in our sample.

209

210 **Positivity profiles according to testing criteria of the USA**

211 **National Comprehensive Cancer Network and Brazilian National** 212 **Health Agency**

213 The sampled individuals were assessed for hereditary cancer testing
214 indication according to two sets of clinical criteria: the NCCN for hereditary

215 breast/ovarian, colorectal, stomach or pancreas cancer syndromes, version
216 3.2019 and 1.2020 and the criteria of the Brazilian National Health Agency
217 (ANS).

218 Among the 1682 individuals in study, 1008 (59.9%) met NCCN 3.2019
219 and 1.2020 criteria for testing, 368 (21.9%) did not meet the criteria and 306 did
220 not have sufficient information for classification. Forty-five patients among the
221 305 that presented pathogenic/likely pathogenic (positive patients) were in the
222 last group, leaving 260 classifiable patients. The true positive rate of NCCN
223 criteria was 215/260 (82.7%) and the false negative rate was 45/260 (17.3%).
224 The F1-measure was 33.9%. Regarding ANS criteria, 660 (39.2%) met the
225 criteria for testing, 691 did not meet and 331 did not have sufficient information
226 for classification. The true positive rate of ANS was 145/260 (55.7%) and the
227 false negative rate was 115/260 (44.2%), and F1-measure was 31.5% (Table
228 2).

229 The group of 215 patients fulfilling testing criteria according to the NCCN
230 had the following genetic profiles: 72 (36.4%) individuals having variants in
231 *BRCA1*, 29 (14.6%) in *BRCA2*, 16 (8.1%) in *PALB2*, 14 (7.1%) in *TP53*, 11
232 (5.6%) in *ATM*, 9 (4.5%) in *CHEK2*, 7 (3.5%) in *RAD50* and *RAD51*, 6 (3.5%) in
233 *RAD51C*, 4 (2.0%) in *MSH6*, 3 (1.5%) in *BRIP1*, *MSH2* and *RAD51D*, 2 (1.0%)
234 in *APC*, *BARD1* and *CDH1* e 8 (4.0%) in other genes (*MEN1*, *MITF*, *MLH1*,
235 *NBN*, *PMS2*, *POLD1*, *PTEN* and *RECQL*).

236 The group of 45 patients who did not meet the NCCN criteria had the
237 following profiles: 9 (20.0%) individuals with variants in *MUTYH*, 7 (16.7%) in
238 *BRCA2*, 6 (14.3%) in *BRCA1*, 5 (11.9%) in *PALB2*, 2 (4.8%) in *ATM*, *CHEK2*,
239 *MLH1*, *MSH6*, *PTEN*, *RET* and *TP53*, besides 10 (23.8%) in other genes

240 (*BARD1, BRIP1, CDK4, FANCC, MRE11A, MSH2, PMS2, PTCH2, RAD51* and
241 *RAD51C*).

242 In summary, both NCCN 1.2020/3.2019 and ANS criteria failed to detect
243 a substantial part of positive patients. The Brazilian criteria fared even worse,
244 missing about 44% of positive patients, versus approximately 17% with NCCN
245 1.2020/3.2019.

246

247 **Geographic distribution of variants**

248 We stratified our data according to each Brazilian state. The results are
249 available in the Table A.5.

250 **Discussion**

251 Cancers were the second most common cause of death worldwide in
252 2018, with 9.6 million deaths (1 every 6 deaths). Lung, prostate, colorectal,
253 stomach and liver are the most common in men, whereas women are more
254 affected by breast, colorectal, lung, cervix and thyroid ¹⁴. The Brazilian National
255 Cancer Institute (INCA) estimates 450,000 new cancer cases per year
256 (excluding non-melanoma skin cancers) for the 2020-2022 triennium ¹⁵.

257 Most tumors are sporadic, caused by somatic genetic events. However,
258 about 10% of the patients carry germline pathogenic variants in cancer
259 predisposition genes such as *BRCA1* or *BRCA2* ¹. The identification of these
260 patients is of utmost clinical importance because early diagnosis of hereditary
261 cancer risk syndromes may improve vigilance and treatment. Therefore, genetic
262 investigation is already a tool of modern oncology ¹⁶.

263 Next generation sequencing (NGS) technologies reduced sequencing
264 costs allowing rapid, precise, and simultaneous analysis of a great quantity of
265 genetic material. NGS has been used to identify genetic causes of rare
266 diseases and cancers, in clinical and research settings. Previously, patients in
267 investigation of HBOC or Lynch syndrome risk would be genotyped by limited,
268 specific panels. Nowadays, as NGS is being largely utilized by clinical
269 laboratories, the patients may undergo genotyping by multigenic panels that
270 allow a better stratification as well as personalized oncologic management ¹⁷.

271 Here, we report the results of our study, the largest conducted in Brazil,
272 with 1682 individuals that underwent genotyping with 27- to 78-genes panels
273 intended to detect germinative variants in cancer predisposition genes. Women
274 are the majority in our sample (92.6%). Consequently, the most prevalent
275 cancers were breast and ovarian (57.7%), colorectal (4.2%) and
276 thyroid/parathyroid (2.1%).

277 The overall positivity rate was 18.1% (305/1682 individuals); 16.0%
278 (269/1682) if individuals with monoallelic *MUTYH* variants are excluded.
279 Considering just *BRCA1/BRCA2* pathogenic/likely pathogenic variants, the
280 positivity rate was only 7.7% (129/1682 individuals). This demonstrates the
281 importance of NGS multigene panels: it reduces the rate of false negatives,
282 providing more information for oncologic management and prognosis.

283 The *BRCA* pathogenic variants positivity rate from our study seems low,
284 but it is not unexpected since our cohort was not specifically selected for any
285 sex, age, ethnicity, or history of cancer. Indeed, since there is significant allelic
286 heterogeneity in *BRCA* genes, there is great variability in positivity rates in other
287 studies ¹⁸. In Brazil, studies of HBOC patients observed positivity rates between

288 1.3%¹⁹ and 27.3%²⁰. In other countries, the positivity rate among sporadic and
289 high-risk hereditary cancer cases varied between 2.6% in the USA²¹ and 27.9%
290 in Japan²² (reviewed in²³). Therefore, our positivity rate is indeed within these
291 ranges.

292 We compared the mutational profile of *BRCA1* and *BRCA2* genes we
293 observed with other 20 Brazilian studies. Among the 56 variants we detected,
294 33 (19 in *BRCA1* and 14 in *BRCA2*) were recurrent in other studies. The five
295 most recurrent variants were: *BRCA1*:c.5266dupC, found by other 18 studies^{18,}
296 ^{20, 24-39}, *BRCA1*:c.3331_3334delCAAG, found in other 12 studies^{18, 20, 24, 27, 29, 31,}
297 ^{32, 34, 35, 37, 39, 40}, *BRCA2*:c.2808_2811delACAA found in other seven studies^{18,}
298 ^{29-31, 34, 35, 39}, *BRCA1*: c.1687C>T found in six studies^{26, 31, 32, 34, 35} and
299 *BRCA1*:c.211A>G found in other five studies^{35-38, 40}.

300 The five most prevalent *BRCA1* mutations among the individuals
301 sampled by our study were c.5266dupC, c.5074+2T>C, c.3331_3334delCAAG,
302 c.1687C>T and c.211A>G. These results partially agree with a worldwide
303 survey that included Brazilian families of women carriers of *BRCA* pathogenic
304 variants. Rebbeck et al. (2018)⁴¹ surveyed 101 Brazilian families and observed
305 c.5266dupC, c.3331_3334delCAAG and c.1687C>T among the five most
306 prevalent *BRCA1* mutations. Therefore, our results agree with three variants.

307 The five most prevalent *BRCA2* variants in our patients were
308 c.2808_2811delACAA, c.9382C>T, c.6024dupG, c.8488-1G>A and
309 c.5216dupA. Only c.2808_2811delACAA was in common with the Rebbeck et
310 al. results⁴¹. Interestingly, they observed c.156_157insAlu among the five most
311 prevalent variation among 49 Brazilian families, but our results place it in sixth
312 place, tied with other variants.

313 The recurrence in independent samples from Brazil indicate the variants
314 are representative of the *BRCA1* and *BRCA2* mutational spectrum in Brazil.
315 Indeed, the *BRCA1*:c.5266dupC and *BRCA2*:c.156_157insAlu (found in other
316 four studies ^{31, 34, 35, 42}) variants are considered as founder mutations coming
317 from European populations and may be found in the individuals from all regions
318 of Brazil ³⁵. Indeed, we detected *BRCA1*: c.5266dupC in individuals from
319 Pernambuco and Alagoas, Northeast Brazil states, as well as in São Paulo
320 (Southeast) and Paraná (South) and *BRCA2*:c.156_157insAlu was detected in
321 an individual from Piauí, also a Northeast state.

322 We also observed some recurrent pathogenic variants in other genes:
323 *TP53*:c.1010G>A, found in four other studies ^{20, 38-40}, *CHEK2*:c.349A>G, found
324 in two other studies ^{38, 43}; *MUTYH*:c.1147delC ⁴³; *MUTYH*:c.1187G>A ³⁸,
325 *MSH2*:c.2152C>T ⁴⁴; *MSH6*:c.3848_3862del ⁴⁵, *MLH1*:c.677G>A ⁴⁴ and
326 *PALB2*:c.2257C>T ⁴⁶. These observations could mean that these variants are
327 important co-players alongside the recurrent *BRCA* variants in the risk of
328 hereditary cancers in Brazilian populations.

329 Transheterozygosity, i.e. heterozygosity at two different loci ⁴⁷, is rare
330 among patients at risk of hereditary cancers. The prevalence of double
331 heterozygosity among *BRCA1/BRCA2* carriers ranges between 1.8% and
332 1.85% ^{48, 49} in the Jewish Ashkenazi populations. Among non-Ashkenazi
333 Europeans, the prevalence is lower, between 0.22% and 0.87% ⁴⁸. An Italian
334 study reported 0.62% ⁵⁰ and a Korean study reported 1.2% ⁵¹. Therefore, our
335 estimate of 0.78% in the Brazilian sample seems plausible.

336 There has been controversy regarding the consequences over the
337 phenotype of *BRCA1/BRCA2* double heterozygote. Earlier reports suggest that

338 they do not have worse phenotypes when comparing to single-variant carriers
339 ^{52, 53}. Bell et al. (2002) ⁵⁴ analyzed three independent samples of tumor tissue
340 from the same *BRCA1/BRCA2* double heterozygote patient and observed that
341 either one or other gene had suffered loss of heterozygosity (LOH) genetic
342 events, suggesting that both genes are functionally equivalent in initiating
343 tumorigenesis in breast tissue. Therefore, double heterozygote status would be
344 equivalent to single-carrier status. Other case reports, case series and review of
345 case reports also suggested that double heterozygote status was not
346 associated with more severe phenotype ^{48, 55, 56}. In contrast, Randall et al.
347 (1998) ⁵⁷ observed LOH in both genes in ovarian tumors, perhaps signaling that
348 the pathogenic events in each tissue are different and not always *BRCA1*
349 mutations are equivalent to *BRCA2* counterparts.

350 However, more recent large surveys have been suggesting that double
351 heterozygote have different phenotypes when compared to single heterozygote
352 individuals. A large survey of 8162 German families with breast/ovarian cancer
353 cases found eight double heterozygote individuals. They observed that they
354 were younger at the onset of their first cancer episode when compared with
355 their single heterozygote relatives and had more severe disease ⁵⁸. A worldwide
356 survey of 32,295 women compared the clinical history of double heterozygote
357 individuals with breast cancer to their single heterozygote counterparts. The
358 same was done for ovarian cancer cases. They observed that clinical
359 characteristics of double heterozygote individuals resemble phenotypes from
360 *BRCA1*-only single heterozygotes, but tumor LOH microsatellite markers
361 patterns are intermediate to the patterns of *BRCA1*-only single heterozygote
362 and *BRCA2*-only single heterozygote. Thus, the authors suggest that the joint

363 effect of *BRCA1/BRCA2* variants are compatible with an additive model ⁴⁷.
364 Another recent study also suggests that the double heterozygote phenotype
365 more closely resembled that of *BRCA1* mutation carriers with poor prognosis
366 factors and proposed a co-dominant model for the joint effects ⁵⁹.

367 In summary, *BRCA1/BRCA2* double heterozygote may have early onset
368 of disease and the phenotype is perhaps similar to the “severe end of spectrum
369 of *BRCA1* mutation carriership” ⁴⁸. We found a single *BRCA1/BRCA2* double
370 heterozygote woman in our sample. She presented personal history of breast
371 cancer. Since she is in her late 40s, her first cancer case must have happened
372 much earlier, however, detailed data on her phenotype is currently lacking.

373 Literature on *BRCA*/other genes double heterozygotes is sparser. Thus,
374 comparison with our results was difficult due to the possible different
375 combinations of variants. For example, Sokolenko et al. (2014) ⁶⁰ found seven
376 digenic combinations double heterozygotes among *BRCA1* and other DNA
377 double-strand repair genes (*BRCA1/CHEK2*, *BRCA1/ATM*, *BRCA1/BLM*,
378 *CHEK2/BLM*, *CHEK2/ATM*, *NBS1/ATM*, and *NBS1/BLM*) in Russian patients:
379 none were observed in our study. They did not observe differences from single
380 heterozygote individuals. In contrast, a case series including a German
381 *BRCA1/PALB2* double heterozygous patient had no early onset but had severe
382 disease (multifocal triple negative ductal carcinoma) ⁶¹. Another case report
383 presented a case of a double heterozygote *APC/MLH1* man with
384 Kashmir/Egyptian ancestry, which had a history of six jejunal cancers ⁶².
385 Therefore, double heterozygosity may have unusual effects on cancer
386 phenotypes. However, we did not find *APC/MLH1* double heterozygous, but

387 found an individual *APC/TP53* double heterozygote, so it is another case
388 warranting further investigation.

389 Perhaps the joint effects of non-*BRCA* variants can be explained in an
390 additive manner as well. Thus, some combinations will result in severe
391 phenotypes while others will not, due to the specific penetrance of each variant.
392 It seems that non-*BRCA* double heterozygotes will need to be analyzed on a
393 case-by-case basis.

394 We found that NCCN 1.2020 criteria missed a substantial proportion of
395 patients that had pathogenic/likely pathogenic variants. Other authors observed
396 the same. We found that NCCN criteria missed a substantial proportion of
397 patients that had pathogenic/likely pathogenic variants. Other authors observed
398 the same. For example, Grindedal et al. (2017)⁶³ investigated *BRCA* mutations
399 in a Norwegian breast cancer cohort and assessed some testing criteria,
400 including NCCN, and found a false negative rate of 15.8%. Yang et al. (2018)⁶⁴
401 investigated 4196 patients genotyped with 40- to 80- genes panels and showed
402 a false negative rate of 13.5% with NCCN criteria. Both were not much far from
403 our estimate of 17% with NCCN 1.2020/3.2019.

404 Other authors proposed changes to NCCN criteria. Alemar et al. (2017)
405³⁴ found that adding criteria that are not included in the NCCN and ANS criteria
406 (e.g. some ASCO criteria^{65, 66}) achieved a higher predictive value, while other
407 authors compared other four algorithms (BOADICEA^{67, 68}, BRCAPRO, Myriad
408⁶⁹ and Manchester score⁷⁰) and observed that the pedigree-based BOADICEA
409 most accurately predicted *BRCA1/BRCA2* variant carrier status in a
410 Southeastern Brazilian population⁷¹. Although NCCN criteria were imperfect,
411 ANS criteria fared worse and a reformulation is warranted.

412 Recently, a panel of Brazilian experts proposed recommendations for
413 improving testing criteria for HBOC risk patients in Brazil. Besides modifying
414 testing criteria, the expert panel also recommended offering risk-reducing
415 surgeries for positive patients. For negative patients, investigating both maternal
416 and paternal lineages is warranted, so the result of models estimating cancer
417 risk can be communicated to the patient. They also suggested that VUS should
418 always be reported and periodically reassessed, but no urgent clinical action is
419 justified since most VUS are constantly reclassified to benign/likely benign
420 categories. Furthermore, patients should be contacted whenever any update in
421 testing protocols or management options should appear ⁷².

422 Our study had some limitations. The NGS panel detects small deletions
423 and duplications up to 17 base-pairs, but large deletions and duplications are
424 not detected by this methodology. Other structural chromosomal changes, such
425 as inversions and translocations are not detected either. If some of these
426 changes are suspected, we recommend using methodologies like array CGH,
427 MLPA, qPCR or FISH to confirm the variant found. Expansion variants of
428 trinucleotide repeats, deep intronic variants or regulatory regions such as
429 promoters are not detectable in the present test. Epigenetic changes are also
430 not detectable by this test. At least for *BRCA* genes though, large
431 rearrangements seem to be uncommon in Brazilian populations ^{35, 42}. Moreover,
432 further phenotype information was missing for several patients, precluding
433 further analyses.

434 Conclusion

435 In conclusion, we genotyped 1682 Brazilian individuals with clinical
436 criteria of hereditary cancer syndrome from all regions of the country with NGS
437 multigenic panels suited for the detection of germline pathogenic variants
438 associated with cancer susceptibility, making it the largest Brazilian study of this
439 nature to date. We observed several *BRCA1* and *BRCA2* recurrent mutations,
440 confirming their presence in the Brazilian mutational spectrum and generated
441 data for other 30 genes and 110 variants with modest penetrance. We also
442 estimated the prevalence of *BRCA* as well as non-*BRCA* double heterozygotes
443 in the Brazilian population. More studies are necessary to discover the
444 implication of transheterozygosity over the phenotype of affected individuals.
445

446 Appendix

447 **Table A.1.** Genotyped genes.

448 **Table A.2.** Ancestry, genetic findings summary, testing criteria, personal and
449 family history.

450 **Table A.3.** Genetic Findings.

451 **Table A.4.** Positivity rate per gene or combination of genes, alongside number
452 of unique pathogenic/likely pathogenic variants detected in each gene. The
453 variants are detailed for transheterozygotes.

454 **Table A.5.** Patients per Brazilian state.

455 References

- 456 1. Samadder NJ, Giridhar KV, Baffy N, Riegert-Johnson D, Couch FJ.
457 Hereditary Cancer Syndromes-A Primer on Diagnosis and Management: Part 1:
458 Breast-Ovarian Cancer Syndromes. *Mayo Clin Proc.* Jun 2019;94(6):1084-1098.
459 doi:10.1016/j.mayocp.2019.02.017
- 460 2. Nagy R, Sweet K, Eng C. Highly penetrant hereditary cancer syndromes.
461 *Oncogene.* 2004;23(38):6445-6470. doi:10.1038/sj.onc.1207714

- 462 3. Zelli V, Compagnoni C, Cannita K, et al. Applications of Next Generation
463 Sequencing to the Analysis of Familial Breast/Ovarian Cancer. *High Throughput*.
464 Jan 10 2020;9(1)doi:10.3390/ht9010001
- 465 4. Xuan J, Yu Y, Qing T, Guo L, Shi L. Next-generation sequencing in the
466 clinic: Promises and challenges. *Cancer Letters*. 2013;340(2):284-295.
467 doi:10.1016/j.canlet.2012.11.025
- 468 5. Yohe S, Thyagarajan B. Review of Clinical Next-Generation Sequencing.
469 *Archives of Pathology & Laboratory Medicine*. 2017;141(11):1544-1557.
470 doi:10.5858/arpa.2016-0501-ra
- 471 6. Machado PM, Brandao RD, Cavaco BM, et al. Screening for a BRCA2
472 rearrangement in high-risk breast/ovarian cancer families: evidence for a founder
473 effect and analysis of the associated phenotypes. *J Clin Oncol*. May 20
474 2007;25(15):2027-34. doi:10.1200/JCO.2006.06.9443
- 475 7. Richards S, Aziz N, Bale S, et al. Standards and guidelines for the
476 interpretation of sequence variants: a joint consensus recommendation of the
477 American College of Medical Genetics and Genomics and the Association for
478 Molecular Pathology. *Genet Med*. May 2015;17(5):405-24.
479 doi:10.1038/gim.2015.30
- 480 8. Biesecker LG, Harrison SM, ClinGen Sequence Variant Interpretation
481 Working G. The ACMG/AMP reputable source criteria for the interpretation of
482 sequence variants. *Genet Med*. Dec 2018;20(12):1687-1688.
483 doi:10.1038/gim.2018.42
- 484 9. Karczewski KJ, Francioli LC, Tiao G, et al. The mutational constraint
485 spectrum quantified from variation in 141,456 humans. *Nature*. 2020/05/01
486 2020;581(7809):434-443. doi:10.1038/s41586-020-2308-7
- 487 10. Karczewski KJ, Weisburd B, Thomas B, et al. The ExAC browser:
488 displaying reference data information from over 60 000 exomes. *Nucleic Acids
489 Research*. 2017;45(D1):D840-D845. doi:10.1093/nar/gkw971
- 490 11. A global reference for human genetic variation. *Nature*.
491 2015;526(7571):68-74. doi:10.1038/nature15393
- 492 12. Landrum MJ, Lee JM, Benson M, et al. ClinVar: improving access to
493 variant interpretations and supporting evidence. *Nucleic Acids Research*.
494 2018;46(D1):D1062-D1067. doi:10.1093/nar/gkx1153
- 495 13. Fokkema IFAC, Taschner PEM, Schaafsma GCP, Celli J, Laros JFJ, Den
496 Dunnen JT. LOVD v.2.0: the next generation in gene variant databases. *Human
497 Mutation*. 2011;32(5):557-563. doi:10.1002/humu.21438
- 498 14. Organization WH. WHO report on cancer: setting priorities, investing
499 wisely and providing care for all. 2020.
- 500 15. Instituto Nacional de Câncer José Alencar Gomes da Silva. Ministério da
501 Saúde. Estimativa 2020: incidência de câncer no Brasil. Rio de Janeiro: Instituto
502 Nacional de Câncer José Alencar Gomes da Silva; 2019. p. 120.
- 503 16. Yoshida R. Hereditary breast and ovarian cancer (HBOC): review of its
504 molecular characteristics, screening, treatment, and prognosis. *Breast Cancer*.
505 Aug 29 2020;doi:10.1007/s12282-020-01148-2
- 506 17. Suwinski P, Ong C, Ling MHT, Poh YM, Khan AM, Ong HS. Advancing
507 Personalized Medicine Through the Application of Whole Exome Sequencing and
508 Big Data Analytics. *Front Genet*. 2019;10:49. doi:10.3389/fgene.2019.00049
- 509 18. Alemar B, Herzog J, Brinckmann Oliveira Netto C, et al. Prevalence of
510 Hispanic BRCA1 and BRCA2 mutations among hereditary breast and ovarian
511 cancer patients from Brazil reveals differences among Latin American

- 512 populations. *Cancer Genet.* Sep 2016;209(9):417-422.
513 doi:10.1016/j.cancergen.2016.06.008
- 514 19. Dillenburger CV, Bandeira IC, Tubino TV, et al. Prevalence of 185delAG and
515 5382insC mutations in BRCA1, and 6174delT in BRCA2 in women of Ashkenazi
516 Jewish origin in southern Brazil. *Genet Mol Biol.* Jul 2012;35(3):599-602.
517 doi:10.1590/S1415-47572012000400009
- 518 20. Cipriano NM, Jr., de Brito AM, de Oliveira ES, et al. Mutation screening of
519 TP53, CHEK2 and BRCA genes in patients at high risk for hereditary breast and
520 ovarian cancer (HBOC) in Brazil. *Breast Cancer.* May 2019;26(3):397-405.
521 doi:10.1007/s12282-018-00938-z
- 522 21. Susswein LR, Marshall ML, Nusbaum R, et al. Pathogenic and likely
523 pathogenic variant prevalence among the first 10,000 patients referred for next-
524 generation cancer panel testing. *Genet Med.* Aug 2016;18(8):823-32.
525 doi:10.1038/gim.2015.166
- 526 22. Sugano K, Nakamura S, Ando J, et al. Cross-sectional analysis of germline
527 BRCA1 and BRCA2 mutations in Japanese patients suspected to have hereditary
528 breast/ovarian cancer. *Cancer Sci.* Oct 2008;99(10):1967-76.
529 doi:10.1111/j.1349-7006.2008.00944.x
- 530 23. Okano M, Nomizu T, Tachibana K, et al. The relationship between BRCA-
531 associated breast cancer and age factors: an analysis of the Japanese HBOC
532 consortium database. *J Hum Genet.* Mar 2021;66(3):307-314.
533 doi:10.1038/s10038-020-00849-y
- 534 24. Lourenço JJ, Vargas FR, Bines J, et al. BRCA1 mutations in Brazilian
535 patients. *Genetics and Molecular Biology.* 2004;27:500-504.
- 536 25. Dufloth RM, Carvalho S, Heinrich JK, et al. Analysis of BRCA1 and BRCA2
537 mutations in Brazilian breast cancer patients with positive family history. *Sao*
538 *Paulo Med J.* Jul 7 2005;123(4):192-7. doi:10.1590/s1516-31802005000400007
- 539 26. Gomes MC, Costa MM, Borojevic R, et al. Prevalence of BRCA1 and
540 BRCA2 mutations in breast cancer patients from Brazil. *Breast Cancer Res Treat.*
541 Jul 2007;103(3):349-53. doi:10.1007/s10549-006-9378-6
- 542 27. Esteves VF, Thuler LC, Amendola LC, et al. Prevalence of BRCA1 and
543 BRCA2 gene mutations in families with medium and high risk of breast and
544 ovarian cancer in Brazil. *Braz J Med Biol Res.* May 2009;42(5):453-7.
545 doi:10.1590/s0100-879x2009000500009
- 546 28. Ewald IP, Izetti P, Vargas FR, et al. Prevalence of the BRCA1 founder
547 mutation c.5266dupin Brazilian individuals at-risk for the hereditary breast and
548 ovarian cancer syndrome. *Hered Cancer Clin Pract.* Dec 20 2011;9(1):12.
549 doi:10.1186/1897-4287-9-12
- 550 29. Carraro DM, Koike Figueira MA, Garcia Lisboa BC, et al. Comprehensive
551 analysis of BRCA1, BRCA2 and TP53 germline mutation and tumor
552 characterization: a portrait of early-onset breast cancer in Brazil. *PLoS One.*
553 2013;8(3):e57581. doi:10.1371/journal.pone.0057581
- 554 30. Silva FC, Lisboa BC, Figueiredo MC, et al. Hereditary breast and ovarian
555 cancer: assessment of point mutations and copy number variations in Brazilian
556 patients. *BMC Med Genet.* May 15 2014;15:55. doi:10.1186/1471-2350-15-55
- 557 31. Fernandes GC, Michelli RA, Galvão HC, et al. Prevalence of
558 BRCA1/BRCA2 mutations in a Brazilian population sample at-risk for hereditary
559 breast cancer and characterization of its genetic ancestry. *Oncotarget.* Dec 6
560 2016;7(49):80465-80481. doi:10.18632/oncotarget.12610

- 561 32. Maistro S, Teixeira N, Encinas G, et al. Germline mutations in BRCA1 and
562 BRCA2 in epithelial ovarian cancer patients in Brazil. *BMC cancer*. Dec 3
563 2016;16(1):934. doi:10.1186/s12885-016-2966-x
- 564 33. de Oliveira ES, Soares BL, Lemos S, et al. Screening of the BRCA1 gene
565 in Brazilian patients with breast and/or ovarian cancer via high-resolution melting
566 reaction analysis. Article. *Fam Cancer*. Apr 2016;15(2):173-181.
567 doi:10.1007/s10689-015-9858-0
- 568 34. Alemar B, Gregório C, Herzog J, et al. BRCA1 and BRCA2 mutational
569 profile and prevalence in hereditary breast and ovarian cancer (HBOC) probands
570 from Southern Brazil: Are international testing criteria appropriate for this specific
571 population? *PLOS ONE*. 2017;12(11):e0187630.
572 doi:10.1371/journal.pone.0187630
- 573 35. Palmero EI, Carraro DM, Alemar B, et al. The germline mutational
574 landscape of BRCA1 and BRCA2 in Brazil. *Sci Rep*. Jun 15 2018;8(1):9188.
575 doi:10.1038/s41598-018-27315-2
- 576 36. Brianese RC, Nakamura KDM, Almeida F, et al. BRCA1 deficiency is a
577 recurrent event in early-onset triple-negative breast cancer: a comprehensive
578 analysis of germline mutations and somatic promoter methylation. *Breast Cancer*
579 *Res Treat*. Feb 2018;167(3):803-814. doi:10.1007/s10549-017-4552-6
- 580 37. Cotrim DP, Ribeiro ARG, Paixão D, et al. Prevalence of BRCA1 and
581 BRCA2 pathogenic and likely pathogenic variants in non-selected ovarian
582 carcinoma patients in Brazil. *BMC cancer*. Jan 3 2019;19(1):4.
583 doi:10.1186/s12885-018-5235-3
- 584 38. Bandeira G, Rocha K, Lazar M, et al. Germline variants of Brazilian women
585 with breast cancer and detection of a novel pathogenic ATM deletion in early-
586 onset breast cancer. *Breast Cancer*. Sep 28 2020;doi:10.1007/s12282-020-
587 01165-1
- 588 39. Da Costa E Silva Carvalho S, Cury NM, Brotto DB, et al. Germline variants
589 in DNA repair genes associated with hereditary breast and ovarian cancer
590 syndrome: analysis of a 21 gene panel in the Brazilian population. *BMC Medical*
591 *Genomics*. 2020;13(1)doi:10.1186/s12920-019-0652-y
- 592 40. Felix GE, Abe-Sandes C, Machado-Lopes TM, et al. Germline mutations
593 in BRCA1, BRCA2, CHEK2 and TP53 in patients at high-risk for HBOC:
594 characterizing a Northeast Brazilian Population. *Hum Genome Var*.
595 2014;1:14012. doi:10.1038/hgv.2014.12
- 596 41. Rebbeck TR, Friebel TM, Friedman E, et al. Mutational spectrum in a
597 worldwide study of 29,700 families with BRCA1 or BRCA2 mutations. *Hum Mutat*.
598 May 2018;39(5):593-620. doi:10.1002/humu.23406
- 599 42. Ewald IP, Cossio SL, Palmero EI, et al. BRCA1 and BRCA2
600 rearrangements in Brazilian individuals with Hereditary Breast and Ovarian
601 Cancer Syndrome. *Genet Mol Biol*. Apr-Jun 2016;39(2):223-31.
602 doi:10.1590/1678-4685-gmb-2014-0350
- 603 43. Felício PS, Grasel RS, Campacci N, et al. Whole-exome sequencing of
604 non-BRCA1/BRCA2 mutation carrier cases at high-risk for hereditary
605 breast/ovarian cancer. *Hum Mutat*. Dec 16 2020;doi:10.1002/humu.24158
- 606 44. Soares BL, Brant AC, Gomes R, et al. Screening for germline mutations in
607 mismatch repair genes in patients with Lynch syndrome by next generation
608 sequencing. *Fam Cancer*. Jul 2018;17(3):387-394. doi:10.1007/s10689-017-
609 0043-5

- 610 45. Rosa RCA, Santis JO, Teixeira LA, et al. Lynch syndrome identification in
611 a Brazilian cohort of endometrial cancer screened by a universal approach.
612 *Gynecol Oncol.* Oct 2020;159(1):229-238. doi:10.1016/j.ygyno.2020.07.013
- 613 46. Gomes R, Spinola PDS, Brant AC, et al. Prevalence of germline variants
614 in consensus moderate-to-high-risk predisposition genes to hereditary breast and
615 ovarian cancer in BRCA1/2-negative Brazilian patients. *Breast Cancer Res Treat.*
616 Oct 30 2020;doi:10.1007/s10549-020-05985-9
- 617 47. Rebbeck TR, Friebel TM, Mitra N, et al. Inheritance of deleterious
618 mutations at both BRCA1 and BRCA2 in an international sample of 32,295
619 women. *Breast Cancer Research.* Nov 11 2016;18112. doi:10.1186/s13058-016-
620 0768-3
- 621 48. Leegte B, van der Hout AH, Deffenbaugh AM, et al. Phenotypic expression
622 of double heterozygosity for BRCA1 and BRCA2 germline mutations. *J Med*
623 *Genet.* Mar 2005;42(3):e20. doi:10.1136/jmg.2004.027243
- 624 49. Lavie O, Narod S, Lejbkowitz F, et al. Double heterozygosity in the BRCA1
625 and BRCA2 genes in the Jewish population. *Ann Oncol.* Apr 2011;22(4):964-966.
626 doi:10.1093/annonc/mdq460
- 627 50. Zuradelli M, Peissel B, Manoukian S, et al. Four new cases of double
628 heterozygosity for BRCA1 and BRCA2 gene mutations: clinical, pathological, and
629 family characteristics. *Breast Cancer Res Treat.* Nov 2010;124(1):251-8.
630 doi:10.1007/s10549-010-0853-8
- 631 51. Noh JM, Choi DH, Nam SJ, et al. Characteristics of double heterozygosity
632 for BRCA1 and BRCA2 germline mutations in Korean breast cancer patients.
633 *Breast Cancer Res Treat.* Jan 2012;131(1):217-22. doi:10.1007/s10549-011-
634 1718-5
- 635 52. Friedman E, Bar-Sade Bruchim R, Kruglikova A, et al. Double
636 heterozygotes for the Ashkenazi founder mutations in BRCA1 and BRCA2 genes.
637 *Am J Hum Genet.* Oct 1998;63(4):1224-7. doi:10.1086/302040
- 638 53. Moslehi R, Russo D, Phelan C, Jack E, Antman K, Narod S. An unaffected
639 individual from a breast/ovarian cancer family with germline mutations in both
640 BRCA1 and BRCA2. *Clin Genet.* Jan 2000;57(1):70-3. doi:10.1034/j.1399-
641 0004.2000.570111.x
- 642 54. Bell DW, Erban J, Sgroi DC, Haber DA. Selective loss of heterozygosity in
643 multiple breast cancers from a carrier of mutations in both BRCA1 and BRCA2.
644 *Cancer Res.* May 15 2002;62(10):2741-3.
- 645 55. Thiffault I, Hamel N, Pal T, et al. Germline truncating mutations in both
646 MSH2 and BRCA2 in a single kindred. *Br J Cancer.* Jan 26 2004;90(2):483-91.
647 doi:10.1038/sj.bjc.6601424
- 648 56. Musolino A, Naldi N, Michiara M, et al. A breast cancer patient from Italy
649 with germline mutations in both the BRCA1 and BRCA2 genes. *Breast Cancer*
650 *Res Treat.* May 2005;91(2):203-5. doi:10.1007/s10549-004-7704-4
- 651 57. Randall TC, Bell KA, Rebane BA, Rubin SC, Boyd J. Germline mutations
652 of the BRCA1 and BRCA2 genes in a breast and ovarian cancer patient. *Gynecol*
653 *Oncol.* Sep 1998;70(3):432-4. doi:10.1006/gyno.1998.5081
- 654 58. Heidemann S, Fischer C, Engel C, et al. Double heterozygosity for
655 mutations in BRCA1 and BRCA2 in German breast cancer patients: implications
656 on test strategies and clinical management. *Breast Cancer Research and*
657 *Treatment.* Aug 2012;134(3):1229-1239. doi:10.1007/s10549-012-2050-4
- 658 59. Le Page C, Rahimi K, Rodrigues M, et al. Clinicopathological features of
659 women with epithelial ovarian cancer and double heterozygosity for BRCA1 and

- 660 BRCA2: A systematic review and case report analysis. *Gynecol Oncol*. Feb
661 2020;156(2):377-386. doi:10.1016/j.ygyno.2019.11.019
- 662 60. Sokolenko AP, Bogdanova N, Kluzniak W, et al. Double heterozygotes
663 among breast cancer patients analyzed for BRCA1, CHEK2, ATM, NBN/NBS1,
664 and BLM germ-line mutations. *Breast Cancer Res Treat*. Jun 2014;145(2):553-
665 62. doi:10.1007/s10549-014-2971-1
- 666 61. Pern F, Bogdanova N, Schürmann P, et al. Mutation analysis of BRCA1,
667 BRCA2, PALB2 and BRD7 in a hospital-based series of German patients with
668 triple-negative breast cancer. *PLoS One*. 2012;7(10):e47993.
669 doi:10.1371/journal.pone.0047993
- 670 62. Lindor NM, Smyrk TC, Buehler S, et al. Multiple jejunal cancers resulting
671 from combination of germline APC and MLH1 mutations. *Fam Cancer*. Dec
672 2012;11(4):667-9. doi:10.1007/s10689-012-9561-3
- 673 63. Grindedal EM, Heramb C, Karsrud I, et al. Current guidelines for BRCA
674 testing of breast cancer patients are insufficient to detect all mutation carriers.
675 *BMC cancer*. 2017;17(1):438-438. doi:10.1186/s12885-017-3422-2
- 676 64. Yang S, Axilbund JE, O'Leary E, et al. Underdiagnosis of Hereditary
677 Breast and Ovarian Cancer in Medicare Patients: Genetic Testing Criteria Miss
678 the Mark. *Ann Surg Oncol*. Oct 2018;25(10):2925-2931. doi:10.1245/s10434-
679 018-6621-4
- 680 65. Statement of the American Society of Clinical Oncology: genetic testing
681 for cancer susceptibility, Adopted on February 20, 1996. *J Clin Oncol*. May
682 1996;14(5):1730-6; discussion 1737-40. doi:10.1200/JCO.1996.14.5.1730
- 683 66. Lu KH, Wood ME, Daniels M, et al. American Society of Clinical Oncology
684 Expert Statement: collection and use of a cancer family history for oncology
685 providers. *J Clin Oncol*. Mar 10 2014;32(8):833-40.
686 doi:10.1200/JCO.2013.50.9257
- 687 67. Antoniou AC, Pharoah PD, McMullan G, et al. A comprehensive model for
688 familial breast cancer incorporating BRCA1, BRCA2 and other genes. *Br J*
689 *Cancer*. Jan 7 2002;86(1):76-83. doi:10.1038/sj.bjc.6600008
- 690 68. Antoniou AC, Pharoah PP, Smith P, Easton DF. The BOADICEA model of
691 genetic susceptibility to breast and ovarian cancer. *Br J Cancer*. Oct 18
692 2004;91(8):1580-90. doi:10.1038/sj.bjc.6602175
- 693 69. Parmigiani G, Berry D, Aguilar O. Determining carrier probabilities for
694 breast cancer-susceptibility genes BRCA1 and BRCA2. *Am J Hum Genet*. Jan
695 1998;62(1):145-58. doi:10.1086/301670
- 696 70. Evans DG, Eccles DM, Rahman N, et al. A new scoring system for the
697 chances of identifying a BRCA1/2 mutation outperforms existing models including
698 BRCAPRO. *J Med Genet*. Jun 2004;41(6):474-80. doi:10.1136/jmg.2003.017996
- 699 71. Teixeira N, Maistro S, Del Pilar Estevez Diz M, et al. Predictability of
700 BRCA1/2 mutation status in patients with ovarian cancer: How to select women
701 for genetic testing in middle-income countries. *Maturitas*. Nov 2017;105:113-118.
702 doi:10.1016/j.maturitas.2017.06.002
- 703 72. Achatz MI, Caleffi M, Guindalini R, Marques RM, Nogueira-Rodrigues A,
704 Ashton-Prolla P. Recommendations for Advancing the Diagnosis and
705 Management of Hereditary Breast and Ovarian Cancer in Brazil. *JCO Glob Oncol*.
706 2020;6:439-452. doi:10.1200/JGO.19.00170
- 707

Table 1. Demographic and clinical characteristics of Brazilian individuals tested genotyped with NGS hereditary cancer panel.

Demographic	N	%
Sex	1682	100
Female	1557	92.6
Male	125	7.4
<i>Age at diagnosis (years)</i>		
<30	79	4.7
30-40	452	26.9
41-50	526	31.3
51-65	465	27.6
>65	160	9.5
<i>Ethnicity</i>		
Multiple ethnicities (admixed)	330	19.6
White	259	15.4
Black	26	1.5
Jewish Ashkenazi	22	1.3
Native indigenous	21	1.2
Asian	17	1.0
No information	1007	59.9
<i>Personal cancer history^a</i>		
Overall	1126	66.9
Breast or ovarian	971	57.7
Colorectal	71	4.2
Thyroid/parathyroid	36	2.1
Prostate	15	0.9
Stomach	14	0.8
Uterus	13	0.8
Kidney	13	0.8
Sarcomas	13	0.8
Leukemia	11	0.6
Skin (non-melanoma)	9	0.5
Pancreas	9	0.5
Other	17	1.0
No cancer history	268	15.9
No information	293	17.4

Family cancer history (first-, second- or third-degree relatives)^a

Overall	1182	70.3
Breast or ovarian	973	57.8
Colorectal	310	18.4
Thyroid/parathyroid	108	6.4
Prostate	339	20.2
Stomach	155	9.2
Uterus	122	7.3
Kidney	45	2.7
Sarcomas	22	1.3
Leukemia	139	8.3
Skin (non-melanoma)	72	4.3
Pancreas	83	4.9
Other	235	14.0
No cancer history	163	9.7
No information	337	20.0

^a Number of individuals with personal history exceeds 1682 because some individuals reported multiple cancer types.

Table 2. NCCN 3.2019/1.2020 and Brazilian ANS testing criteria performance.

Decision	NGS testing		Row totals
	Positive patients	VUS/Negative patients	
<i>NCCN 3.2019/1.2020</i>			
At risk	215	793	1008
No risk	45	323	368
Column totals	260	1116	1376
Insufficient information: 306			
<i>Brazilian ANS</i>			
At risk	145	515	660
No risk	115	576	691
Column totals	260	1091	1351
Insufficient information: 331			





NCCN: sensitivity = 82.7%, specificity = 28.9%, false negative rate = 17.3%, F1-measure = 33.9%.

ANS: sensitivity = 55.8%, specificity = 52.8%, false negative rate = 44.2% F1-measure = 31.5%.

Figure captions

Figure 1. Variants profiles. (A) Distribution of patients according to genetic findings. P/LP = patients with pathogenic/likely pathogenic, VUS = patients with variants of uncertain significance (N = 1682). (B) Distribution of P/LP variants per gene. (C) P/LP variants functional annotation. (D) Distribution of VUS per gene. Lynch syndrome genes have been grouped together in (C) and (D).

Figure 2. Heatmap representing the distribution of pathogenic/likely pathogenic (P/LP) transheterozygotes in the sample. The top line represents the number of patients in each column. The single heterozygotes (n=290) are distributed in the main diagonal. Transheterozygotes (n=15) are distributed in the inferior half (14 double-heterozygotes and 1 triple-heterozygote). The total number of variants are 321 ($290 \times 1 + 14 \times 2 + 1 \times 3 = 321$).

A**B****C****D**

Total 305 patients, 321 P/LP patients

85 45 40 25 16 14 11 8 7 7 6 6 5 4 4 4 2 3 2 1 2 2 0 1 1 1 1 1 1 1 0 1

